Last updated: February 19, 2026
This analysis examines World Intellectual Property Organization (WIPO) patent application WO2006090845, detailing its claims, scope, and the surrounding patent landscape. The application, filed by the University of Florida Research Foundation, Inc., concerns a novel class of compounds for treating metabolic disorders, particularly type 2 diabetes.
What is the Core Innovation Claimed in WO2006090845?
The central invention disclosed in WO2006090845 is a series of substituted imidazopyridine compounds and their pharmaceutical compositions. These compounds are described as potent activators of the peroxisome proliferator-activated receptor gamma (PPARγ) [1]. PPARγ is a nuclear receptor that plays a crucial role in regulating glucose metabolism and fatty acid storage. Activation of PPARγ can lead to improved insulin sensitivity and reduced blood glucose levels, making it a validated target for type 2 diabetes treatment.
What are the Key Structural and Functional Aspects of the Claimed Compounds?
The patent application describes a broad genus of imidazopyridine derivatives defined by specific chemical structures. These structures generally involve an imidazo[1,2-a]pyridine core substituted at various positions with aryl, heteroaryl, alkyl, and other functional groups. The core structure is depicted as follows:
Figure 1: Generic Imidazopyridine Structure (Simplified)
R1
|
N
/ \
C C
/ \ / \
C N C
| | |
C---C---C
| |
R2 R3
(Note: This is a simplified representation. The actual claims define specific positions and allowable substituents R1, R2, and R3 with precise chemical definitions).
The compounds are claimed to possess desirable pharmacological properties, including high affinity and efficacy for PPARγ activation. The patent emphasizes that these compounds offer advantages over existing PPARγ agonists, such as potentially improved safety profiles and efficacy in treating metabolic syndrome [1].
How Broad is the Claimed Scope of WO2006090845?
WO2006090845 asserts broad claims covering the novel chemical entities, their synthesis, pharmaceutical compositions containing them, and methods of treating conditions associated with insulin resistance.
What Are the Principal Claim Categories?
The patent application includes several categories of claims:
- Compound Claims: These are typically independent claims that define the chemical structures themselves. They cover the specific imidazopyridine derivatives and related analogs. The claims define the imidazo[1,2-a]pyridine core and the substituents at various positions (e.g., C2, C3, C5, C6, C7, C8) with ranges of allowable chemical groups. For instance, claims might specify an aryl group at R1, a specific linker at R2, and various functional groups at R3, encompassing a wide chemical space [1].
- Composition Claims: These claims cover pharmaceutical compositions comprising at least one of the claimed compounds and a pharmaceutically acceptable carrier, diluent, or excipient. This is crucial for the practical application of the invention, enabling formulation into dosage forms like tablets, capsules, or injectables [1].
- Method of Treatment Claims: These claims outline the use of the claimed compounds or compositions in treating specific medical conditions. The primary focus is on metabolic disorders, including type 2 diabetes, impaired glucose tolerance, insulin resistance, and related complications such as hyperlipidemia and obesity [1].
- Process Claims: While less common for novel compounds, process claims might cover specific synthetic routes or intermediates used to manufacture the claimed active pharmaceutical ingredients (APIs).
What Specific Indications Are Targeted?
The patent explicitly targets diseases and conditions where PPARγ modulation is beneficial. These include:
- Type 2 Diabetes Mellitus
- Impaired Glucose Tolerance
- Insulin Resistance Syndrome
- Metabolic Syndrome
- Obesity
- Hyperlipidemia (Dyslipidemia)
- Related cardiovascular complications arising from these conditions [1].
What is the Status and Prosecution History of WO2006090845?
WO2006090845 is an international patent application filed under the Patent Cooperation Treaty (PCT). Its publication date is August 17, 2006 [1]. As an international application, it designates numerous countries and has undergone or is undergoing national/regional phase processing in various jurisdictions.
What Does the International Application Publication Mean?
The publication of WO2006090845 means the invention is publicly disclosed. This publication date establishes a prior art reference for subsequent patent applications filed worldwide. The application now allows the applicant to pursue patent protection in individual countries or regions by entering the national/regional phase before the expiry of the 30-month period from the priority date (if any) or the international filing date.
Has This Application Been Granted as a Patent in Key Jurisdictions?
As of the latest available data, the University of Florida Research Foundation, Inc. has pursued patent protection for these compounds in multiple territories. For example, granted patents stemming from this PCT application or related divisional applications may exist in:
- United States: Applications have been filed and some may have progressed to grant.
- Europe: European Patent applications have been processed through the European Patent Office (EPO).
- Other major markets: Including Japan, China, Canada, and Australia.
The specific grant status and patent numbers in each jurisdiction would require a detailed country-by-country search. However, the broad scope of the initial PCT application suggests a strategy to secure protection globally.
What is the Competitive Patent Landscape for PPARγ Agonists?
The field of PPARγ agonists has a rich and complex patent history, largely driven by the therapeutic importance of this target for diabetes. WO2006090845 entered this landscape at a time when several PPARγ agonists, such as thiazolidinediones (TZDs) like pioglitazone (Actos) and rosiglitazone (Avandia), were already established or in late-stage development.
Who are the Major Players in PPARγ Agonist Patents?
Key entities that have historically held significant patent portfolios in the PPARγ space include:
- Pharmaceutical Companies: Takeda Pharmaceutical Company (for pioglitazone), GlaxoSmithKline (for rosiglitazone), Merck & Co., Novartis, Bristol-Myers Squibb, and Eli Lilly and Company.
- Academic Institutions: As demonstrated by WO2006090845, universities have also been active in discovering and patenting novel PPARγ modulators.
How Does WO2006090845 Differentiate Itself?
The primary differentiation for the compounds claimed in WO2006090845 lies in their novel imidazopyridine scaffold, distinct from the TZD class. While TZDs have demonstrated efficacy, they also faced concerns regarding side effects, including weight gain, fluid retention, and potential cardiovascular risks. The University of Florida's invention aimed to develop compounds with a potentially improved therapeutic index, offering the benefits of PPARγ activation with a reduced side effect profile [1].
This distinction is critical in patentability. For WO2006090845 to be granted and remain valid, its claims must demonstrate novelty, inventiveness (non-obviousness), and utility over the existing art, including previously patented TZDs and any other PPARγ modulators disclosed before its priority date.
What Are the Implications of Patent Expirations for Older PPARγ Agonists?
The patent landscape for older PPARγ agonists like pioglitazone and rosiglitazone has seen significant shifts due to patent expiries. This has opened the door for generic competition, reducing prices and increasing market access. However, patent protection for novel compounds, like those claimed in WO2006090845, is crucial for the originating entities to recoup R&D investments and achieve market exclusivity. The patent term for WO2006090845, if granted, would typically extend for 20 years from the international filing date, subject to potential patent term extensions in some jurisdictions.
What are the Potential Commercial and R&D Implications of WO2006090845?
The patent WO2006090845, along with its granted national/regional patents, represents an opportunity for the University of Florida Research Foundation, Inc. and its potential licensees or partners.
What is the R&D Value Proposition?
The value proposition of the WO2006090845 technology lies in its potential to deliver a new generation of metabolic drugs. Successful development could address unmet medical needs in diabetes and related disorders, particularly if the compounds demonstrate a superior safety and efficacy profile compared to existing therapies. The broad claims also provide a strong foundation for a pipeline of related compounds.
What are the Licensing and Commercialization Pathways?
The University of Florida Research Foundation, Inc. typically licenses its patented technologies to commercial entities for further development and marketing. Potential pathways include:
- Exclusive Licensing: Granting a single company the exclusive rights to develop and commercialize the technology in specific territories or for specific indications.
- Co-development Agreements: Partnering with a pharmaceutical company to share the costs and risks of clinical development and commercialization.
- Spin-off Company: Establishing a new company dedicated to advancing the technology, often with venture capital funding.
The commercial success hinges on several factors, including the clinical trial results, regulatory approvals, market acceptance, and the competitive environment at the time of launch.
What are the Potential Challenges?
- Clinical Development Risk: The path from preclinical discovery to a marketed drug is fraught with risk. Compounds may fail in clinical trials due to lack of efficacy or unacceptable toxicity.
- Regulatory Hurdles: Obtaining approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a rigorous and time-consuming process.
- Market Competition: The diabetes market is highly competitive, with numerous treatment options available. New entrants must demonstrate clear advantages.
- Patent Litigation: The strength and scope of the patents are critical for defending against potential infringement. Broad patents are more susceptible to challenges from competitors seeking to invalidate them.
Key Takeaways
WIPO patent application WO2006090845, filed by the University of Florida Research Foundation, Inc., claims a class of substituted imidazopyridine compounds as PPARγ activators for treating metabolic disorders, primarily type 2 diabetes. The application discloses novel chemical entities, pharmaceutical compositions, and methods of treatment. The broad claims encompass a significant chemical space, aiming to differentiate from existing therapies like TZDs by offering a potentially improved safety profile. As an international application, it has served as a basis for pursuing national and regional patent protection globally. The competitive landscape for PPARγ modulators is well-established, with WO2006090845 seeking to carve out a distinct therapeutic niche. Commercialization hinges on successful clinical development, regulatory approval, and market positioning against established and emerging therapies.
Frequently Asked Questions
-
What is the patent status of WO2006090845?
WO2006090845 is an international PCT application published on August 17, 2006. It has served as the basis for pursuing national and regional patent applications in various countries. Its current status is the prosecution of these national/regional phase applications, with potential grants in key jurisdictions.
-
What specific medical conditions do the claimed compounds aim to treat?
The primary indications targeted are metabolic disorders, including type 2 diabetes mellitus, impaired glucose tolerance, insulin resistance syndrome, metabolic syndrome, obesity, and hyperlipidemia.
-
How do the claimed compounds differ from existing diabetes medications like pioglitazone or rosiglitazone?
The claimed compounds are based on a novel imidazopyridine chemical structure, distinct from the thiazolidinedione (TZD) class of drugs to which pioglitazone and rosiglitazone belong. The invention aims for improved efficacy and a potentially better safety profile compared to existing PPARγ agonists.
-
Who owns the intellectual property rights associated with WO2006090845?
The intellectual property rights are held by the University of Florida Research Foundation, Inc.
-
What are the typical next steps after a PCT application like WO2006090845 is filed?
After the international publication, the applicant typically enters the "national phase" in countries where they seek patent protection. This involves filing separate applications in each chosen country or region (e.g., USPTO for the US, EPO for Europe) and undergoing substantive examination by the respective patent offices.
Citations
[1] University of Florida Research Foundation, Inc. (2006). Imidazopyridine compounds and uses thereof. WO2006090845 A1. World Intellectual Property Organization.
